Asahi Intecc Co., Ltd. (7747.T): PESTLE Analysis [Apr-2026 Updated]

Asahi Intecc sits at a powerful strategic nexus-bolstered by market-leading guidewire technology, deep R&D and manufacturing scale across ASEAN, strong patent protection and growing digital and sustainability initiatives-yet it must navigate margin pressure from reimbursement cuts, rising raw‑material and regulatory costs, and currency and trade volatility; demographic trends, expanding emerging‑market healthcare spend, AI/robotics integration and value‑based care offer clear growth lanes, while intensified global regulation, patent litigation and supply‑chain risks threaten execution-making its ability to convert technological advantage and geographic diversification into durable, cost‑efficient global expansion the story to watch.

Asahi Intecc Co., Ltd. (7747.T) - PESTLE Analysis: Political

Trade tensions shape Japanese medical device exports. Escalating trade frictions between major markets - notably US-China tariff measures and periodic Japan-China diplomatic strains - increase transaction costs and logistical uncertainty for precision medical device exporters such as Asahi Intecc. Japan's medical device export value was approximately ¥2.3 trillion in FY2023 (MOF/Japan industry reports), with tariff variability and non-tariff barriers able to affect margins by an estimated 1-4% on affected product lines. Export controls on advanced manufacturing components and intermittent customs delays can extend lead times by 10-25% for some overseas shipments.

Reimbursement reforms squeeze device margins. Major payers in Asahi's target markets (Japan, US, EU) continue to implement cost-containment and DRG-based adjustments. In Japan, reimbursement revision cycles typically reduce device reimbursement levels by 1-3% annually in aggregate; the 2024 revision included targeted cuts to high-cost consumables. In the US and EU, value-assessment frameworks and bundled payments reduce per-procedure device revenues by 5-15% for products lacking demonstrated cost-effectiveness. The net effect is downward pressure on average selling prices and shorter product life-cycle revenue windows.

Southeast Asian stability supports higher-volume production. Political stability and manufacturing incentives across ASEAN - notably Thailand, Vietnam, and Malaysia - promote offshore assembly and contract manufacturing. ASEAN FDI inflows to manufacturing sectors reached over USD 100 billion in 2023, with medical devices among prioritized industries. For Asahi, relocating or expanding operations in the region can lower labor-related COGS by 15-30% versus Japan-based assembly while benefiting from trade agreements (e.g., CPTPP/ RCEP) that reduce tariffs to near 0-5% for intra-regional exports.

Global shift to value-based care influences purchasing. Governments and public health systems are increasingly favoring procurement tied to outcomes and total cost of care. Procurement tenders now often require health-economic evidence, real-world outcomes data, or risk-sharing pricing. This political trend reallocates purchasing toward devices demonstrating measurable reductions in hospitalization or readmission rates; products lacking robust HEOR data may see contract win rates drop by 20-40% in competitive tenders.

International regulatory alignment lowers market entry barriers. Political cooperation and harmonization initiatives (IMDRF, Japan PMDA alignment with FDA/EMA standards, and mutual recognition agreements under RCEP) streamline regulatory pathways. Average time-to-market for Class II/III devices can decline by 6-12 months where reliance pathways and common technical documentation are accepted. For Asahi, this reduces pre-market compliance costs by an estimated 10-20% and accelerates return on investment for new product launches.

Political Factor	Direct Impact on Asahi	Estimated Financial/Operational Effect	Likelihood (1-5)
US-China trade tensions	Export cost volatility, potential tariffs on components	Margin impact: 1-4%; lead-time increases 10-20%	4
Japan reimbursement revisions	Reduced device reimbursement; pricing pressure	Revenue reduction per unit: 1-3% annually (Japan); competitive pressure globally 5-15%	5
ASEAN political stability & incentives	Offshore production expansion opportunity	COGS reduction: 15-30%; improved tariff access 0-5%	4
Value-based procurement policies	Procurement shifts to outcome-based purchases	Contract win-rate variance: -20% to +15% depending on HEOR	4
Regulatory harmonization (IMDRF/RCEP)	Simplified approvals, faster market entry	Time-to-market shorter by 6-12 months; compliance cost -10-20%	3

• Operational responses: diversify supply base across RCEP/ASEAN to mitigate tariff risk and achieve 15-30% lower assembly COGS.
• Commercial strategy: invest in HEOR and real-world data generation to protect tender win rates and offset reimbursement pressures; target 10-20% adoption lift in value-based tenders.
• Regulatory tactics: leverage regulatory reliance pathways and harmonized submissions to reduce time-to-market by ~6-12 months.
• Policy engagement: monitor trade policy and engage industry associations to influence tariff and non-tariff barrier negotiations.

Asahi Intecc Co., Ltd. (7747.T) - PESTLE Analysis: Economic

Yen stability benefits overseas revenue: A stable or weaker yen versus major currencies (USD/EUR) amplifies reported JPY revenue from overseas sales. Asahi Intecc derives a significant portion of sales from international markets-primarily North America, Europe and Asia-so FX translation materially affects consolidated revenue and operating profit. When USD/JPY moves from 105 to 145, for example, a constant-dollar overseas sales base can lift reported JPY revenue by roughly 38%.

Hedging mitigates currency volatility: The company employs active currency management-forward contracts, natural hedges via local invoicing and procurement-to reduce short-term FX swings. Typical corporate hedging coverage for forecasted export receivables ranges between 40%-80% over rolling 6-12 month horizons, reducing quarterly EBIT volatility from currency swings while leaving some exposure to benefit from favorable currency moves.

Metric	Typical Value / Range	Notes
Overseas sales share	~55%-70%	North America & Europe largest contributors
Hedging coverage (forecasted receivables)	40%-80%	6-12 month rolling program
R&D investment (% of sales)	~5%-8%	Consistent reinvestment to maintain device pipeline
Raw material inflation (YoY)	+6%-12%	Precision metals, polymers, and electronic components
Freight & energy cost impact on margins	~1-3 percentage points	Volatile during global supply chain disruptions

Low domestic rates fund R&D investment: Japan's historically low short-term interest rates (policy rate at or near 0% to slightly negative in recent years) lower borrowing costs for capex and working capital, enabling sustained investment into R&D and manufacturing automation. Lower cost of capital allows the firm to finance product development and facility upgrades without large increases in interest expense, supporting R&D intensity of approximately 5%-8% of consolidated sales.

Global inflation drives raw material costs: Pass-through limitations and supplier lead times make Asahi Intecc vulnerable to increases in the price of stainless steel, specialty polymers, electronic components and packaging materials. Industry observations point to YoY raw material cost inflation of roughly 6%-12% in high-pressure periods; acute spikes in specific components can raise bill-of-materials (BOM) costs by several percentage points, compressing gross margins if price increases cannot be passed to customers immediately.

• Key cost drivers: precision metals, polymer compounds, PCB/electronics, sterile packaging.
• Typical supplier lead time volatility: 4-12 weeks (components) to 12+ weeks (custom parts).
• Potential margin impact: BOM cost increases can reduce gross margin by 1-4 pts before pricing actions.

Logistics and energy costs pressure margins: Rising air/sea freight rates, port congestion and higher energy prices in production regions increase operating expenses. Freight rate volatility has in past cycles moved total logistics spend by +20%-60% year-on-year, translating into a 0.5-2.0 percentage point drag on operating margin depending on product mix and inventory strategy. Energy cost spikes (electricity/gas) in key manufacturing locations can add incremental manufacturing overheads, particularly for clean-room operations and sterilization processes.

Operational levers and financial sensitivity: The company manages economic pressures by adjusting pricing, optimizing procurement (multi-sourcing, long-term contracts), increasing local sourcing in major markets to reduce FX and freight exposure, and maintaining a contingency buffer in working capital. Sensitivity analysis typically models ±10% changes in USD/JPY, ±8-12% in raw material costs and ±20-50% in freight rates to assess EPS and FCF impacts.

Asahi Intecc Co., Ltd. (7747.T) - PESTLE Analysis: Social

Aging populations drive rising demand for interventions. Japan's population aged 65+ reached approximately 29.1% in 2023, while OECD countries average near 18%. Globally, the population aged 60+ is projected to grow from 1.0 billion in 2020 to 1.4 billion by 2030 (UN). Older cohorts have higher incidence of vascular disease, peripheral artery disease (PAD) and coronary artery disease (CAD), increasing demand for diagnostic and interventional devices such as guidewires, microcatheters and atherectomy tools supplied by Asahi Intecc. In Japan, cardiovascular intervention volumes grew ~2-4% annually pre-pandemic; in aging markets growth is expected to outpace population growth by 2025-2030.

Chronic cardiovascular disease prevalence expands market. Cardiovascular diseases caused an estimated 17.9 million deaths in 2019 (WHO), remaining the leading cause of mortality. Prevalence of PAD affects ~200 million people worldwide; coronary artery disease prevalence exceeds 100 million diagnosed cases in major markets. Diabetes prevalence (global adult prevalence ~10.5% in 2021) further elevates vascular complication rates. Rising prevalence increases procedure volumes for percutaneous coronary intervention (PCI) and peripheral interventions, directly expanding the addressable market for Asahi's core product lines.

Preference for minimally invasive procedures grows. The global minimally invasive cardiac and peripheral intervention devices market was valued at approximately USD 35-45 billion in 2023 with a CAGR of ~6-8% forecast to 2028. Patient and physician preference shifts toward shorter hospital stays, reduced recovery time and lower complication rates favor catheter-based and transcatheter solutions over open surgery. Adoption rates for transcatheter procedures (e.g., TAVI, PCI, peripheral angioplasty) rose by double digits in many markets between 2015-2022, supporting sustained demand for high-performance guidewires and microcatheters.

Health access expansion boosts regional demand. Expansion of public and private health insurance coverage in emerging markets (India, Southeast Asia, Latin America, parts of Africa) is increasing access to interventional cardiology and radiology services. Out-of-pocket spending remains high in some regions, but growth in universal health coverage programs and hospital infrastructure investments is enabling more procedures. Market expansion rates in developing regions for cardiovascular intervention devices have been estimated at 8-12% CAGR, compared with 3-5% in more saturated developed markets.

Global screening programs support early intervention growth. Increased adoption of cardiovascular risk screening (lipids, CT calcium scoring, ABI for PAD) and population-level initiatives for diabetes and hypertension detection raise rates of early diagnosis. Early detection drives elective and preventive interventional procedures, increasing requirement for diagnostic catheters and guidewires. National programs in China, India and parts of Latin America target screening scale-ups to millions annually; organized screening and referral pathways correlate with higher procedure uptakes.

Social Driver	Key Metrics / Data	Impact on Asahi Intecc
Aging population	Japan 65+ = 29.1% (2023); Global 60+ projected 1.4B (2030)	Higher procedure volumes for CAD/PAD; sustained demand for guidewires and microcatheters
Cardiovascular disease prevalence	CVD deaths ~17.9M (2019); PAD ~200M worldwide; CAD >100M cases	Expands addressable patient base; increases recurrent device purchases
Minimally invasive preference	Market size USD 35-45B (2023); CAGR ~6-8% to 2028	Favors advanced, precision devices; premium pricing and R&D opportunities
Health access expansion	Emerging markets CAGR 8-12% vs developed 3-5%	New geographic revenue streams; need for cost-competitive product variants
Screening programs	Large-scale national screening initiatives in China/India/LA; millions screened annually	Increases early interventions; demand for diagnostic and therapeutic device portfolios

Implications for strategy and operations:

• Product development: focus on steerability, thin-profile guidewires and microcatheters suited to elderly, calcified anatomy.
• Commercial focus: expand presence in high-growth emerging markets and non-urban referral centers where screening increases case volumes.
• Pricing and portfolio: develop tiered offerings-premium for advanced markets, cost-effective lines for expanding access markets.
• Training and support: invest in physician education for minimally invasive techniques to accelerate adoption of Asahi devices.
• Data and evidence: generate real-world outcomes and registry data demonstrating benefits in older and comorbid populations to support payer coverage.

Asahi Intecc Co., Ltd. (7747.T) - PESTLE Analysis: Technological

AI-guided procedures reduce radiation and time. Adoption of AI-driven image guidance and procedural planning in interventional cardiology and endovascular therapy is driving measurable improvements: AI-enabled navigation systems can reduce fluoroscopy time by 30-50% and overall procedure time by 20-40% in selected cases, lowering operator radiation exposure and increasing lab throughput. For Asahi Intecc, integration of AI into guidewire/catheter selection and real-time tip-tracking informs product design (e.g., optimized tip shapes, coatings) and supports value propositions in hospitals seeking to cut procedure times and improve case turnover; hospitals report potential per-procedure cost savings of USD 300-1,200 when procedure time and consumable use decline.

Ultra-fine wire drawing advances catheter performance. Advances in metallurgical processing and precision wire drawing enable guidewire core diameters below 0.10 mm (100 µm) and tip configurations that balance pushability, torque transmission and flexibility. Asahi's manufacturing capability around ultra-fine stainless steel and nitinol processing yields:

• Higher tip control: torque response improvements of 10-25% versus previous-generation wires
• Smaller-profile devices: enabling access to tortuous distal vasculature and supporting minimally invasive indications
• Yield and scrap reduction targets: process controls aim to reduce micro-defect scrap rates to <2% per batch

These material and process improvements support premium pricing (5-20% ASP premium for specialized wires) and expand addressable procedure categories.

Industry 4.0 boosts manufacturing efficiency. Investment in sensors, IIoT connectivity, predictive maintenance, and digital quality systems reduces downtime and improves output consistency. Typical KPIs observed in medical device factories adopting Industry 4.0 include:

• Overall Equipment Effectiveness (OEE) uplift: +8-20%
• Reduction in unplanned downtime: 30-60%
• Quality defect rate reduction: 15-40%

Capital expenditure for smart-factory upgrades can range from JPY 200-1,000 million per major production line, but payback periods are often 18-36 months. For Asahi, leveraging Industry 4.0 supports scale-up to meet annual growth rates in vascular device demand of ~6-10% globally and improves margins by reducing variable manufacturing costs.

Robotics-enabled surgery creates new consumable needs. The rapid expansion of robotic-assisted endovascular and cardiovascular platforms (robotic surgery market CAGR ~18-22% through 2028) increases demand for compatible consumables: steerable guidewires, robotic-actuated catheter interfaces, and single-use tip modules. Key commercialization implications:

• Design-for-robotics: mechanical interface standards and automated connector specs become critical
• Recurring revenue: consumable attach rates per robotic case can drive 20-40% higher per-case device spend versus manual procedures
• Partnership value: strategic OEM ties with robot platform providers can secure format standards and preferred-supplier status

Asahi can capture incremental revenue by certifying products for leading robotic platforms and adjusting production to just-in-time supply models aligned with hospital robotics adoption curves.

Digital health data compliance underpins device innovation. Device connectivity-embedded sensors, procedure logs, cloud analytics-enables product differentiation but requires strict compliance with global data regimes. Relevant metrics and impacts:

Compliance Area	Risk/Requirement	Financial/Operational Impact
GDPR / EU	Data protection by design; breach fines up to 4% of global turnover or EUR 20M	Potential multi‑million EUR fines; mandatory design changes increase R&D by 5-12%
HIPAA / US	Protected health information safeguards; breach notification and remediation	Cost per record breach average USD 408 (2023 IBM); full remediation can exceed USD 2-10M
Medical Device Regulations (MDR / IVDR)	Clinical evidence and cybersecurity requirements	Extended certification timelines; conformity costs can add 1-3% to product lifecycle costs
Local data residency	Storage and processing within jurisdiction	Infrastructure costs: local cloud/hosting premiums 10-30% vs global providers

To commercialize connected devices and AI analytics, Asahi must invest in secure software development lifecycle processes, continuous post-market surveillance, and data governance frameworks-typically 1-3% of revenue annually for medium-large medical device firms-while leveraging compliant data to enable outcomes-based contracting and product differentiation.

Asahi Intecc Co., Ltd. (7747.T) - PESTLE Analysis: Legal

MDR compliance raises CE-related costs: The EU Medical Device Regulation (MDR 2017/745) has tightened conformity assessment, clinical evidence and post-market surveillance requirements compared with the Medical Device Directive. Industry assessments estimate an increase in direct compliance costs of approximately 20-50% for device manufacturers, driven by more rigorous clinical data generation, Notified Body capacity shortages and expanded Technical Documentation requirements. For a precision medical-device manufacturer like Asahi Intecc, MDR-driven costs manifest as higher testing and clinical-investment budgets, extended conformity timelines and increased reliance on fewer qualified Notified Bodies.

FDA approval timelines affect time-to-market: US regulatory pathways vary by risk class. 510(k) clearances commonly complete in ~90 days when dossiers are complete, though real-world median times including interactions often extend to 4-6 months. PMA pathways for high-risk devices typically take multiple years - historically median review plus evidence-generation periods of 3-7 years. These differences materially affect product launch sequencing and revenue recognition for devices such as interventional cardiology and guidewire products. Delay in FDA authorization can defer US market entry and reduce first-mover advantages.

IP protection and cross-border litigation pressures: Medical-device companies face patent, trade secret and design-right disputes across jurisdictions. Patent enforcement costs for cross-border litigation commonly range from several hundred thousand to multi-million-dollar budgets per case, depending on scope and venues (e.g., Japan, US, EU). Asahi Intecc's core technologies (e.g., nitinol shaping, hydrophilic coatings) require proactive patent filing and monitoring to prevent infringement and to defend against competitor challenges. The risk of injunctive relief in the US and Europe can disrupt manufacturing or distribution streams rapidly.

Data privacy and cross-border data transfer rules: Clinical data, device performance logs and customer records are increasingly regulated. GDPR exposures include administrative fines up to €20 million or 4% of global annual turnover, whichever is higher. Japan's APPI and other national laws impose additional safeguards and restrictions on cross-border transfers. For Asahi Intecc, obligations include lawful bases for processing clinical and customer data, data processing agreements with distributors, implementation of adequate transfer mechanisms (e.g., SCCs or local adequacy determinations), and technical controls to secure patient-identifiable and device telemetry data.

Regulatory fees and post-market surveillance obligations: Under MDR and many national regimes, manufacturers face increased fees for conformity assessment, vigilance reporting, Periodic Safety Update Reports (PSURs) and device registration. Typical recurring obligations include UDI assignment and maintenance, PSURs submitted annually for Class III/implantable and periodically for other classes, and mandatory field safety corrective action reporting within defined timeframes (e.g., 15 days for serious incidents in many jurisdictions). These obligations drive ongoing regulatory headcount and third-party vendor costs.

The following table summarizes key legal topics, practical requirements, typical timelines/cost impacts and implications for Asahi Intecc:

Legal Area	Key Requirement	Typical Timeline / Cost Impact	Implication for Asahi Intecc
MDR (EU)	Expanded clinical evidence; Notified Body assessment; UDI; PSURs	20-50% increase in compliance spend; Notified Body waits of 3-12+ months	Higher pre-market spend, slower CE renewals, need for stronger clinical programs
FDA (US)	510(k) clearance or PMA approval; Quality System Regulation (21 CFR 820)	510(k): ~3-6 months typical; PMA: 3-7+ years including trials; review fees may exceed $100k	Staggered market entry; potential multi-year revenue deferral for high-risk devices
Intellectual Property	Patents, trade secrets, design protections; global portfolio maintenance	Litigation costs: $100ks-$M+ per major case; annual prosecution/renewal costs per family $10k-$30k	Necessitates robust prosecution strategy and enforcement budget; risk of injunctions
Data Privacy	GDPR, APPI, local privacy laws; lawful processing and cross-border transfer safeguards	Potential fines up to €20M/4% global turnover; program implementation costs €100k-€1M+ depending on scale	Requires legal/compliance resources, DPIAs, contracts, and secure data infrastructure
Post-Market & Fees	Vigilance reporting, field safety notices, regulatory maintenance fees, device registration	Annual recurring costs vary by market; PSUR and vigilance program staffing costs significant (FTEs or vendors)	Ongoing OpEx burden; faster detection/response capability needed to avoid penalties and recalls

Key legal compliance activities and controls to operationalize (examples):

• Maintain and budget for expanded clinical studies and real-world evidence programs to satisfy MDR and PMA expectations.
• Strengthen IP portfolio monitoring and enforcement across Japan, US, EU and emerging markets; budget for litigation reserves.
• Implement a comprehensive data protection program: DPIAs, Data Processing Agreements, Standard Contractual Clauses, encryption and access controls.
• Scale post-market surveillance infrastructure: UDI management, PSUR production cadence, adverse event handling workflows and regulatory reporting SLAs.
• Monitor regulatory fee schedules and plan for recurring registration and Notified Body expenses in annual financial forecasts.

Asahi Intecc Co., Ltd. (7747.T) - PESTLE Analysis: Environmental

Asahi Intecc has publicly aligned its environmental strategy with industry expectations for medical device manufacturers, prioritizing greenhouse gas (GHG) reductions, energy transition, materials stewardship and regulatory compliance across its global manufacturing footprint. The group's environmental program centers on measurable carbon reduction targets, renewable energy adoption, circularity initiatives, chemical substitution, and rigorous environmental audits tied to RoHS/REACH and regional norms.

Carbon reduction targets and renewable energy adoption

Asahi Intecc announced a corporate commitment consistent with Japan's national and sectoral goals: a long-term net-zero aspiration by 2050 with interim targets to 2030. Key disclosed metrics and targets include:

• Scope 1 + 2 GHG reduction target: 30% reduction by 2030 versus FY2019 baseline (target year specified in corporate ESG filings).
• Renewable electricity target: 50% of global electricity consumption from renewables by 2030, progressing to 100% by 2050.
• Energy intensity: 15% reduction in energy use per unit of production between 2020 and 2026 through equipment upgrades and process optimization.

These targets are enforced through capital allocation for energy-efficiency projects and Power Purchase Agreements (PPAs) in key facilities in Japan, Vietnam and the Philippines where occupancy and tariff structures allow corporate procurement of renewable power.

Circular economy and waste diversion programs

Operational initiatives focus on waste minimization in precision-machining and polymer processing lines, reuse of packaging and partnerships for medical-device component take-back in select markets. Current operational performance and goals include:

• Waste diversion rate (recycling + recovery): 82% across manufacturing facilities in FY2023.
• Hazardous waste generation: 0.12 tonnes per 1,000 units produced in FY2023, with a target to reduce to 0.09 t/1,000 units by 2026.
• Packaging reduction: 18% absolute reduction in single-use external packaging weight between FY2020 and FY2023.

Below is a table summarizing key environmental performance indicators and targets for material and waste management.

Indicator	FY2020	FY2023	Target (2030)
Waste diversion rate	68%	82%	90%
Hazardous waste (t/1,000 units)	0.18	0.12	0.06
Packaging weight reduction	0% (baseline)	18% reduction	35% reduction
Recycled material content in components	5%	12%	25%

Renewable energy sourcing cuts emissions

Renewable sourcing has a direct impact on Scope 2 emissions. Progress indicators include:

• Percentage of electricity from renewables: 22% in FY2023 (corporate PPAs and onsite solar), targeting 50% by 2030.
• Absolute Scope 1+2 emissions: 45,000 tCO2e in FY2023, down from 64,000 tCO2e in FY2019 (cumulative reduction ~29.7%).
• Estimated emissions avoided via renewables in FY2023: ~9,800 tCO2e.

Financial impact of renewable transition is managed through CAPEX allocations: ¥2.3 billion earmarked for energy-efficiency and renewable projects across 2024-2027, with expected payback periods of 3-7 years and internal carbon price assumptions of ¥8,000 per tCO2e applied in project evaluations.

Chemical compliance and substitution drive materials

Asahi Intecc operates in a heavily regulated product space where chemical composition affects biocompatibility and compliance. Key drivers and actions:

• RoHS/REACH adherence for electrical/mechanical subcomponents; REACH candidates/SVHC monitoring with active substitution programs for phthalates, lead-tin solders and certain fluorinated polymers.
• Materials R&D budget: ¥450 million annually (FY2024 plan) focused on alternative polymers and lower-impact sterilization-compatible materials.
• Supplier engagement: ~1,200 tier-1 suppliers screened for chemical compliance in FY2023; 14% required material reformulation or certification updates.

Environmental audits and RoHS/compliance elevate costs

Regulatory compliance and third-party audits increase operational spend and capital requirements. Current cost and audit metrics:

• Annual EHS and compliance audit coverage: 100% of manufacturing sites audited at least once per year; high-risk sites audited semi-annually.
• Compliance-related operating expense: ¥520 million in FY2023 (including testing, certification, audit fees and supplier remediation), up 12% year-on-year driven by expanded testing requirements for EU MDR and US FDA submissions.
• Expected incremental compliance spend: additional ¥160-220 million annually through 2026 to meet evolving RoHS/REACH/MDR requirements and to implement substitution programs.

Below is a table summarizing audit frequency, compliance costs and projected incremental spend.

Item	FY2022	FY2023	Projected FY2026
Sites audited annually	85%	100%	100%
Compliance Opex (¥ million)	410	520	700
Incremental annual spend for regulatory changes (¥ million)	-	-	160-220
Supplier remediation actions (count)	96	168	200 (est.)